Back to Trials
NCT07258836PHASE1RecruitingAccepts Healthy Volunteers

A Study of [18F]LY4214835 in Healthy Volunteers and Participants With Cancer

Eli Lilly and Company

Start Date

12/22/2025

Completion Date

1/1/2027

Summary

The purpose of the study is to check how safe and well-tolerated \[18F\]LY4214835 injection is in healthy participants and participants with cancer. The study drug will be administered intravenously (IV) (into a vein). Participation in the study will last approximately 35 days.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: * Cohort 1 * Have a radiologically, cytologically, or histologically confirmed diagnosis of cancer * Are treatment-naïve to a systemic cancer therapy, OR have a documented disease progression on standard-of-care treatment (for example, failure of chemotherapy, targeted therapy or immunotherapy) * Have at least 1 imageable tumor that is 15 millimeter (mm) or larger in the longest diameter * Cohort 2 * Are overtly healthy at the Screening Visit and upon reporting to the clinic for the positron emission tomography (PET) Imaging Visit, as determined by medical evaluation including updated medical history, vital signs, physical examination, laboratory tests, and electrocardiogram (ECG) Exclusion Criteria: * Are pregnant or intend to become pregnant during their participation in the study * Are breastfeeding or intending to breastfeed during their participation in the study * Have a history of risk factors for Torsades de Pointes (for example, heart failure, hypokalemia, family history of Long QT Syndrome) * Are actively receiving cancer therapy or are in between cycles of treatment * Have a marked baseline prolongation of QT/corrected QT interval (QTc) interval (for example, repeated demonstration of a QTc interval greater than (\>) 450 millisecond (ms)

Interventions

DRUG

LY4214835

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

NeoplasmsHealthy

Locations

Invicro

New Haven, Connecticut 06510

United States

Boston Medical Center

Boston, Massachusetts 02118

United States

Massachusetts General Hospital (MGH)

Charlestown, Massachusetts 02129

United States

BAMF Health Inc.

Grand Rapids, Michigan 49503

United States

Memorial Sloan Kettering Cancer Center

New York, New York 10065

United States

Ichor Research

Syracuse, New York 13210

United States